<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731637</url>
  </required_header>
  <id_info>
    <org_study_id>17-011305</org_study_id>
    <secondary_id>U01DK108328</secondary_id>
    <nct_id>NCT03731637</nct_id>
  </id_info>
  <brief_title>A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort</brief_title>
  <acronym>NOD</acronym>
  <official_title>A Prospective Study to Establish a New Onset Hyperglycemia and Diabetes (NOD) Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Create a large biobank of blood samples and data from subjects with new onset hyperglycemia
      and diabetes (NOD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective NOD Cohort of 10,000 eligible, enrolled subjects will be assembled over the
      next 3 years, with each patient participating for up to 3 years from the date they meet
      biochemical (glycemic) criteria for diabetes. Sites electronic medical record databases or
      other avenues for recruitment, such as physician and self referral, will be utilized to
      identify subjects meeting criteria for NOD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of pancreatic ductal adenocarcinoma in new-onset hyperglycemia and diabetes</measure>
    <time_frame>3 years</time_frame>
    <description>Enrolled subjects will be followed for three years to determine the 1-year, 2-year, 3-year incidence rates of PDAC in new-onset hyperglycemia and diabetes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine sensitivity and specificity of serum CA 19-9 in pre-symptomatic pancreatic ductal adenocarcinoma in subjects with new-onset hyperglycemia and diabetes</measure>
    <time_frame>3 years</time_frame>
    <description>We will retrospectively measure serum CA 19-9 in blood collected at baseline and at each subsequent blood draw to determine its ability to predict pancreatic cancer in presymptomatic subjects. We will also collect blood for future biomarker testing.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Diabetes</condition>
  <condition>Type2 Diabetes</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>New-onset diabetes</arm_group_label>
    <description>Subjects with biochemically-defined new-onset diabetes</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Research Blood Collection
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who newly meet criteria for diabetes
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able and willing to provide informed consent and sign an informed consent
             form.

          -  Subject must sign an authorization for the release of their protected health
             information.

          -  Subject must be ≥50 and ≤85 years of age at the time of enrollment.

          -  Subject must have hyperglycemia and/or diabetes as one of the following within 90 days
             prior to enrollment:

               -  All glycemic parameters must be measured in an outpatient setting

        A. (1) Hemoglobin A1c (HbA1c) ≥ 6.5% present, OR

        B. Any (2) PDMs present on consecutive or simultaneous testing:

          -  Fasting Blood Glucose (FBG) ≥126 mg/dl

          -  Hemoglobin A1c (HbA1c) ≥ 6.5%

          -  Random Blood Glucose (RBG) ≥200 mg/dl

          -  2h Post Glucose (PG) ≥200mg (11.1 mmol/L) during OGTT (oral glucose tolerance test),
             OR

        C. Any (1) PDM present followed by an anti-diabetes medication

          -  Subject must have &gt;1 glycemic parameter measured in the 18 months prior to the
             elevated index lab without meeting inclusion criteria A, B, or C.

          -  Subject must be willing to provide blood samples (fasting) at baseline, 6, 12, and 24
             months post-enrollment.

          -  Subject or authorized representative must be willing to complete a detailed
             questionnaire.

        Exclusion Criteria:

          -  Subject must not have any past history of hyperglycemia and/or diabetes as defined by
             inclusion criteria A, B, or C

               -  Transient diabetes (e.g. gestational and steroid-induced) is not an exclusion.

          -  Subject must not be on active treatment for cancer, carry a current diagnosis of any
             cancer, and/or investigated for suspicion of recurrence of past cancer (except
             non-melanoma skin cancer or carcinoma in-situ of the cervix).

               -  Ongoing work up for suspicion of pancreatic cancer is not an exclusion.

          -  Subject must not have any past history of pancreatic cancer.

          -  Subject must not be on anti-diabetes medications prior to the elevated index lab.

          -  Subject must not be on chronic or acute use of steroid medications within 90 days of
             the elevated index lab.

               -  Allowed: Nasal, topical steroids, oral budesonide, ophthalmic

          -  Subject must not have had a recent (within 1 week of the elevated index lab)
             intra-articular steroid injection.

          -  In the physician's and/or investigator's judgement, subject does not have any
             co-morbidities that limit the subject's participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suresh Chari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anirban Maitra, MBBS</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Nguyen, MPH, MSW</last_name>
    <phone>206-667-2258</phone>
    <email>sarah.nguyen@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaiser Permanente Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bechien Wu, MD</last_name>
      <phone>323-783-7890</phone>
      <email>Bechien.U.Wu@kp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Pandol, MD</last_name>
      <phone>310-423-6082</phone>
      <email>stephen.pandol@cshs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northern California</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Van Den Eeden, MD</last_name>
      <phone>510-591-3718</phone>
      <email>Stephen.VanDenEeden@kp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Park, MD</last_name>
      <phone>650-723-4102</phone>
      <email>wgpark@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Hughes, MD</last_name>
      <phone>352-265-0761</phone>
      <email>Steven.Hughes@surgery.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univeristy Hospital, Indian University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeb Saeed, MD</last_name>
      <email>zisaeed@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Health System</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Stella, MD</last_name>
      <email>Philip.stella@stjoeshealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Petersen, Ph.D.</last_name>
      <email>Petersen.Gloria@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bradley, MD</last_name>
      <phone>614-685-3333</phone>
      <email>david.bradley@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randall Brand, MD</last_name>
      <phone>412-623-0021</phone>
      <email>brandre@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Fisher, MD</last_name>
      <phone>713-798-4321</phone>
      <email>wfisher@bcm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005 Aug;129(2):504-11.</citation>
    <PMID>16083707</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharma A, Smyrk TC, Levy MJ, Topazian MA, Chari ST. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Gastroenterology. 2018 Aug;155(2):490-500.e2. doi: 10.1053/j.gastro.2018.04.025. Epub 2018 Apr 30.</citation>
    <PMID>29723506</PMID>
  </results_reference>
  <results_reference>
    <citation>Setiawan VW, Stram DO, Porcel J, Chari ST, Maskarinec G, Le Marchand L, Wilkens LR, Haiman CA, Pandol SJ, Monroe KR. Pancreatic Cancer Following Incident Diabetes in African Americans and Latinos: The Multiethnic Cohort. J Natl Cancer Inst. 2019 Jan 1;111(1):27-33. doi: 10.1093/jnci/djy090.</citation>
    <PMID>29917105</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Ziding Feng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>New Onset Diabetes</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

